| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
NLRP3[1].
Antcin A is a potent NLRP3 inhibitor. The NLRP3 inflammasome is a critical component of the innate immune system that mediates inflammatory responses. By inhibiting NLRP3, Antcin A suppresses the activation of caspase-1 and the production of pro-inflammatory cytokines such as IL-1β and IL-18. |
|---|---|
| ln Vitro |
In vitro, Antcin A exhibits strong anti-inflammatory effects, functioning similarly to glucocorticoids. It inhibits the activation of the NLRP3 inflammasome, reducing the secretion of pro-inflammatory cytokines. Additionally, it has shown anti-tumor effects in various cancer cell lines, making it a promising compound for cancer research.
|
| ln Vivo |
In vivo, Antcin A has demonstrated significant anti-inflammatory and anti-tumor activities in preclinical models. Its ability to inhibit NLRP3 inflammasome activation makes it a potential therapeutic agent for inflammatory diseases. Its anti-tumor effects have been observed in various cancer models.
|
| Enzyme Assay |
The inhibition of NLRP3 by Antcin A is typically assessed using cell-based assays that measure inflammasome activation. Macrophages or other immune cells are treated with the compound and then stimulated with NLRP3 agonists (e.g., LPS + ATP or nigericin). The release of IL-1β and IL-18 is measured by ELISA, and caspase-1 activation is assessed by Western blotting.
|
| Cell Assay |
Cellular assays for Antcin A involve treating immune cells (such as macrophages or monocytes) with the compound and measuring inflammatory responses. The production of pro-inflammatory cytokines (IL-1β, IL-18, TNF-α) is measured by ELISA or qRT-PCR. The activation of NF-κB and other signaling pathways is assessed by Western blotting.
|
| Animal Protocol |
In vivo studies of Antcin A are conducted in animal models of inflammatory diseases, such as LPS-induced sepsis or DSS-induced colitis. The compound is typically administered via intraperitoneal (i.p.) injection or oral gavage. Inflammatory markers in serum and tissues are measured, and tissue histology is evaluated.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Antcin A are not extensively characterized in publicly available sources. As a natural product, it is expected to be metabolized through standard detoxification pathways. It is typically formulated in DMSO or other organic solvents for in vitro studies.
|
| Toxicity/Toxicokinetics |
Antcin A is intended for research use only and is not for therapeutic or diagnostic use in humans. As a natural product, its toxicological profile is not fully characterized. Standard laboratory safety practices should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Reports indicate that camphor fungi from Taiwan contain lysergic acid-8,24(28)-diene-26-acid, 4-methyl-3,11-dioxo-,(4α,5α)-, and there is relevant data.
Antcin A is a steroid-like phytochemical from Antrodia cinnamomea with strong anti-inflammatory and anti-tumor properties. It is a potent NLRP3 inhibitor. This compound is a valuable research tool for studying inflammatory diseases and cancer. |
| Molecular Formula |
C29H42O4
|
|---|---|
| Molecular Weight |
454.64
|
| Exact Mass |
454.308
|
| CAS # |
163597-24-8
|
| PubChem CID |
10004121
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
6.396
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
33
|
| Complexity |
913
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
CC1C(=O)CCC2(C)C1CCC1=C2C(=O)CC2(C)C1CCC2C(C)CCC(=C)C(C)C(O)=O
|
| InChi Key |
WTSUWKBKPMVEBO-QMHPZZQYSA-N
|
| InChi Code |
InChI=1S/C29H42O4/c1-16(18(3)27(32)33)7-8-17(2)21-11-12-23-20-9-10-22-19(4)24(30)13-14-28(22,5)26(20)25(31)15-29(21,23)6/h17-19,21-23H,1,7-15H2,2-6H3,(H,32,33)/t17-,18?,19+,21-,22+,23+,28+,29-/m1/s1
|
| Chemical Name |
(6R)-2-methyl-3-methylidene-6-[(4S,5S,10S,13R,14R,17R)-4,10,13-trimethyl-3,11-dioxo-2,4,5,6,7,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-17-yl]heptanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1995 mL | 10.9977 mL | 21.9954 mL | |
| 5 mM | 0.4399 mL | 2.1995 mL | 4.3991 mL | |
| 10 mM | 0.2200 mL | 1.0998 mL | 2.1995 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
